boltbio.comHealthcareFounded: 2015Funding to Date: $64.6MM
Bolt Biotherapeutics is a biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients.
View Enterprise Value for Bolt Biotherapeutics.